SCHEMBL18170700

SCHEMBL18170700

Cc1ccsc1C(=O)Nc1ccc(-c2ccccc2)c2c1C(=O)NC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.55
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
PPARG P37231 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
NAMPT P43490 1/20 0.41
PKM P14618 1/20 0.40
GRM1 Q13255 1/20 0.40
ANO1 Q5XXA6 1/20 0.40
ROCK2 O75116 1/20 0.39
RET P07949 1/20 0.39
FLT1 P17948 1/20 0.39
EPHA2 P29317 1/20 0.39
AXL P30530 1/20 0.39
FLT4 P35916 1/20 0.39
FLT3 P36888 1/20 0.39
FRK P42685 1/20 0.39
AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18170894 0.88 KDR (0.50) KDRPKMMEN1KMT2AALDH1A1
SCHEMBL18170512 0.88 KDR (0.50) KDRALDH1A1RXFP1
SCHEMBL18170808 0.83 KDR (0.58) KDRHPGDROCK2RETFLT1
SCHEMBL18170580 0.82 KDR (0.58) KDRROCK2RETFLT1EPHA2
SCHEMBL18170754 0.82 KDR (0.52) KDRHPGDSMN1; SMN2NPC1RAB9A
SCHEMBL18171025 0.81 KDR (0.69) KDRAURKBMEN1KMT2A
SCHEMBL18170569 0.81 KDR (0.69) KDRNPC1RAB9AROCK2RET
SCHEMBL18170794 0.80 KDR (0.58) KDRROCK2RETFLT1EPHA2
SCHEMBL18170968 0.80 KDR (0.63) KDRHPGDSMN1; SMN2NPC1RAB9A
SCHEMBL18170447 0.80 KDR (0.55) KDRHPGDSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US claimed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US claimed
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US disclosed
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TNIK, TNK1, NFKBIA KDR 1662/4885HPGD 4720/4885SMN1; SMN2 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.